Advertisement

Annals of Surgical Oncology

, Volume 25, Supplement 3, pp 886–887 | Cite as

ASO Author Reflections: Surgery and Bevacizumab in Ovarian Cancer

  • Marco Petrillo
  • Giovanni Scambia
  • Anna Fagotti
ASO Author Reflections
  • 59 Downloads

Notes

Disclosures

The study commented upon was supported by an unrestricted grant provided by Roche. The authors have no conflicts of interest to disclose.

References

  1. 1.
    Perren TJ, Swart AM, Pfisterer J, et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011;365:2484–96.CrossRefGoogle Scholar
  2. 2.
    Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365:2473–83.CrossRefGoogle Scholar
  3. 3.
    Eveno C, Passot G, Goére´ D, et al. Bevacizumab doubles the early postoperative complication rate after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol. 2014;21:1792–800.CrossRefGoogle Scholar
  4. 4.
    Petrillo M, Nero C, Carbone V, Bruno M, Scambia G, Fagotti F. Systematic review of cytoreductive surgery and bevacizumab-containing chemotherapy in advanced ovarian cancer: focus on safety. Ann Surg Oncol. 2018;25:247–54.CrossRefGoogle Scholar
  5. 5.
    Duska LR, Java JJ, Cohn DE, Burger RA. Risk factors for readmission in patients with ovarian, fallopian tube, and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236). Gynecol Oncol. 2015;139:221–7.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2018

Authors and Affiliations

  • Marco Petrillo
    • 1
    • 2
  • Giovanni Scambia
    • 3
  • Anna Fagotti
    • 3
  1. 1.Gynecologic and Obstetric Clinic, Department of Clinical and Experimental MedicineUniversity of SassariSassariItaly
  2. 2.PhD School in Biomedical SciencesUniversity of SassariSassariItaly
  3. 3.Department of Woman and Child HealthIRCCS Fondazione Policlinico Agostino GemelliRomeItaly

Personalised recommendations